Normal ambulatory blood pressure in young adults with 21-hydroxylase enzyme deficiency undergoing glucocorticoid replacement therapy

Autor(es)

Borges, Juliano Henrique ; Camargo, Daniela Albiero ; Sewaybricker, Leticia Esposito ; Santoro, Renata Isa ; de Oliveira, Daniel Minutti ; de Lemos-Marini, Sofia Helena Valente ; Geloneze, Bruno ; Guerra-Junior, Gil ; Goncalves, Ezequiel Moreira

• Tipo de documento: Artigo Científico
• Fonte: ARCHIVES OF ENDOCRINOLOGY METABOLISM; v. 67, n. 1, p. 9-pg., 2023-01-01.

Resumo

Objective: Herein, we compared ambulatory blood pressure (ABP) between young adults with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase enzyme (21OHase) deficiency and a control group. Additionally, we analyzed correlations between the glucocorticoid dose and androgen levels and ABP parameters. Subjects and methods: This case-control study included 18 patients (6 males and 12 females) and 19 controls (8 males and 11 females) matched by age (18-31 years). ABP monitoring was used to estimate blood pressure (BP) over a 24-h period. Results: No difference was noted between patients and controls in terms of systolic BP (males, 115.5 +/- 5.6 vs. 117.0 +/- 9.3, P = 0.733; and females, 106.4 +/- 7.9 vs. 108.4 +/- 7.6, P = 0.556, respectively) and diastolic BP during 24 h (males, 62.8 +/- 7.5 vs. 66.2 +/- 5.6, P = 0.349; and females, 62.7 +/- 4.9 vs. 62.3 +/- 4.9, P = 0.818, respectively). Systolic and diastolic BP and pulse pressure during daytime and nocturnal periods were similar between patients and controls. Furthermore, no differences were detected in the percentage of load and impaired nocturnal dipping of systolic and diastolic BP between patients and controls during the 24-h period. Additionally, the glucocorticoid dose (varying between r =-0.24 to 0.13, P > 0.05) and androgens levels (varying between r = 0.01 to 0.14, P > 0.05) were not associated with ABP parameters. Conclusion: No signs of an elevated risk for hypertension were observed based on ABP monitoring in young adults with CAH attributed to 21OHase deficiency undergoing glucocorticoid replacement therapy. (AU)

• Processo FAPESP: 11/23460-1 - Risco cardiometabólico em pacientes com a forma clássica da Hiperplasia Adrenal Congênita por deficiência da enzima 21-hidroxilase.
• Beneficiário: Ezequiel Moreira Gonçalves
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 17/00657-0 - Influência do diabetes induzido por dieta no desenvolvimento de gliose hipotalâmica em adolescentes com obesidade
• Beneficiário: Leticia Esposito Sewaybricker
• Modalidade de apoio: Bolsas no Exterior - Pesquisa
• Processo FAPESP: 12/16778-8 - Avaliação cardiometabólica e do padrão de secreção de células beta pancreáticas em pacientes portadores de hiperplasia adrenal congênita
• Beneficiário: Gil Guerra Júnior
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 14/20186-4 - Relação entre a pressão arterial e gordura corporal em pacientes com hiperplasia adrenal congênita por deficiência da enzima 21-hidroxilase
• Beneficiário: Daniela Albiero Camargo
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica